Questions addressed:
- Will the Pharma Strategy successfully tackle the onshoring of production of lifesaving pharmaceuticals? What is the timeline?
- How will an EU-wide reshoring strategy work alongside national programs? Could companies double up on incentives from member states and the EU? And is there a risk of member states competition over medicines manufacturing?
- Incentives, tax breaks, reduced barriers to entry... what are the most effective tools to strengthen European manufacturing and which combination will work best for both industry and patients?
- How quickly can it translate into concrete steps against shortages of medicines?
- Who is going to shoulder the added cost of EU-made medicines - pharma, health insurers, governments and taxpayers?
With:
Philippe Drechsle, vice president generics Europe, Teva
Andrzej Rys, director, health systems, medical products and innovation, DG SANTE, European Commission
Charlotte Roffiaen, European policy advisor, France Assos Santé
Visit our website: [ Ссылка ]
-------- Social Media --------
Follow us on Twitter: [ Ссылка ] | [ Ссылка ]
Follow us on Facebook: [ Ссылка ]
Follow us on LinkedIn: [ Ссылка ]
